EUVIMEDEUVIMED entdecken
Crossref

Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?

Jennifer Abbasi

JAMA · 10.11.2026 · 336 (18) · 1587

DOI: 10.1001/jama.2026.20002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 10.11.2026. Verfasst von Jennifer Abbasi. Beteiligte Einrichtung: Director, Medical News, JAMA. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Medical News article discusses the top-line results from the Lp(a)HORIZON trial, which investigated lipoprotein(a) lowering to reduce major adverse cardiovascular events.

Autor:innen und Institutionen

  • Director, Medical News, JAMA.

Zitieren

APA

Abbasi, J. (2026). Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?. JAMA, 336(18), 1587. https://doi.org/10.1001/jama.2026.20002

Vancouver

Abbasi J. Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?. JAMA. 2026;336(18):1587. doi:10.1001/jama.2026.20002

BibTeX
@article{Abbasi2026,
  author = {Abbasi, Jennifer},
  title = {Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?},
  journal = {JAMA},
  year = {2026},
  volume = {336},
  number = {18},
  pages = {1587},
  doi = {10.1001/jama.2026.20002}
}
Kostenlos starten →